Latest Intelligence in Europe

Published within

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Xarelto data raise questions at the 2010 American Heart Association Scientific Sessions

Results from the ROCKET-AF trial of Xarelto in stroke prevention in atrial fibrillation have been presented at this year's Scientific Sessions of the American Heart Association. While positive, the data show that Xarelto has by no means outperformed Pradaxa. Clinicians may start to see the two drugs as complementary alternatives, based on their respective performance in various subgroups.

Published By Datamonitor
16 Nov 2010
CommentWire
CommentWire

Wyevale: room to grow

Sir Tom Hunter and Baugur are leading a consortium to take over Wyevale Garden Centres in a deal that values the UK's largest garden retailer at GBP310 million. Despite a recent downturn in sales, the underlying prospects for the retailer are promising and the investment could drive further growth.

Published By Datamonitor
21 Apr 2006
CommentWire
CommentWire

Wyeth: UK offers Efexor relief

Having concluded a new review of the latest safety evidence related to Wyeth's serotonin and noradrenergic reuptake inhibitor Efexor, UK regulators have eased the barriers restricting use of the drug. The updated prescribing advice should help Wyeth stabilize sales of Efexor while also enabling the company to plan more effectively for the launch of its follow-on compound, desvenlafaxine.

Published By Datamonitor
02 Jun 2006
CommentWire
CommentWire

Wyeth: Torisel valuable for poor-risk patients

The European Commission has granted regulatory approval to Wyeth's Torisel, making it the first mTOR kinase inhibitor to reach the EU market. While renal cell carcinoma patients are becoming increasingly well served in terms of treatment options, Torisel represents a valuable addition for poor-risk patients, who traditionally have been the most difficult to treat.

Published By Datamonitor
27 Nov 2007
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: diversity key to growth

Wyeth's performance in 2002 was negatively affected by its heavy reliance on its Women's Health franchise. With the anticipated launch of Flumist, it is expected that 2003 will mark the beginning of Wyeth's transition from a reliance on HRT treatments to a more diversified portfolio.<BR />

Published By Datamonitor
05 Jun 2003
CommentWire
CommentWire

Wyeth: Big Pharma continues its shopping spree

The current economic environment has paved the way for leading pharmaceutical firms to sweep in and buy up smaller players, highlighted by Wyeth's potential acquisition of Crucell and Merck & Co's strategy to aggressively look for targets in 2009. An increasing number of pharmaceutical majors are likely to use this approach to strengthen their biologic portfolios and access novel pipeline drugs.

Published By Datamonitor
09 Jan 2009
CommentWire
CommentWire

Wyeth: a question of consolidation

Revenues at Wyeth have climbed despite declining sales of key products such as Premarin and Prevnar. Litigation expenses continue to impact the bottom line, but a cash injection resulting from the merger of Immunex and Amgen has improved the company's financial situation. There are signs the company could be ripe for consolidation once more.

Published By Datamonitor
30 Jan 2003
Expert View
Expert View

Wunelli and SSP bet on the mass market

In the burgeoning telematics space Wunelli and SSP have partnered to launch a smartphone-based product targeting the mass market. The simplicity of such a solution will appeal to consumers, but data quality issues could limit the benefits to insurers.

Published By Datamonitor
14 May 2013
CommentWire
CommentWire

WSA: the friendlier face of alcohol regulation

In response to a government interim report on alcohol harm reduction, the WSA has released its own recommendations. Unsurprisingly, it argues against the more drastic actions the government proposes. However, the WSA's less costly suggestions are nothing new. They require little effort on the part of the industry and it is likely that they will also have little effect.

Published By Datamonitor
15 Dec 2003

« | ... | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | ... | » »|

No help is available.